Bigfoot Biomedical® Closes Series C Financing with $55 Million as Company Readies for FDA Submission of Bigfoot Unity Funding to Support its Breakthrough Therapy and Telemedicine Solutions for People Living with Insulin-Requiring Type 1 and Type 2 Diabetes MILPITAS, Calif., June 2, 2020-- Bigfoot Biomedical, Inc. announced today that the company has raised a total of $55 million to close its Series C equity financing. The round was led by Abbott with support from existing investors, including Quadrant Capital Advisors, Senvest Capital, Janus Henderson and Cormorant Asset Management, along with new investors including Smile Group.